Korea Exchange · Healthcare
Prestige BioPharma stock from India: price, numbers and tax
Prestige BioPharma (950210) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Prestige BioPharma at a glance
- Price
- ₩5,960.00+₩30.00 (0.51%)
- Market cap
- ₩358.17B
- Day range
- ₩5,850.00 – ₩6,020.00
- P/E
- -3.87
- Dividend yield
- None
- Volume
- 19.68K
- 1 month
- -5.85%
- 6 months
- -34.58%
- YTD
- -53.62%
- 1 year
- -54.22%
- 5 years
- -77.42%
Prestige BioPharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩26.1B | ₩14.3B | ₩689.1M | ₩161.8M | ₩0.0 |
| Gross profit | −₩30.8B | −₩24.0B | −₩528.8M | ₩127.9M | −₩3.9B |
| Operating income | −₩93.6B | −₩67.3B | −₩62.8B | ₩1.0B | −₩118.8B |
| Net income | −₩91.5B | ₩22.3B | −₩32.9B | ₩17.6B | −₩211.5B |
| Earnings per share | −₩1,522.10 | ₩370.61 | −₩547.81 | ₩292.35 | −₩3,518.53 |
| EBITDA | −₩60.8B | ₩33.3B | −₩31.1B | ₩10.5B | −₩206.9B |
| Total assets | ₩741.4B | ₩741.9B | ₩711.7B | ₩741.6B | ₩499.8B |
| Total debt | ₩106.1B | ₩144.2B | ₩89.7B | ₩86.2B | ₩4.2B |
| Cash and short-term investments | ₩63.0B | ₩173.7B | ₩228.8B | ₩301.4B | ₩303.3B |
| Shareholders' equity | ₩434.2B | ₩408.9B | ₩439.1B | ₩450.5B | ₩429.9B |
| Operating cash flow | −₩56.5B | −₩54.3B | −₩48.0B | −₩60.3B | −₩45.9B |
| Free cash flow | −₩62.5B | −₩95.0B | −₩76.0B | −₩125.9B | −₩114.0B |
| Capital expenditure | −₩6.0B | −₩40.7B | −₩28.0B | −₩65.6B | −₩68.1B |
Fiscal years as reported, the latest ending 30 Jun 2026. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Pharmicell | 005690.KS | ₩12,860.00 | ₩771.65B |
| Chabiotech | 085660.KQ | ₩8,200.00 | ₩758.52B |
| GC | 005257.KS | ₩18,000.00 | ₩541.01B |
| Proteina | 468530.KQ | ₩44,400.00 | ₩485.71B |
| GC | 005250.KS | ₩9,750.00 | ₩438.49B |
| Medy-Tox | 086900.KQ | ₩65,900.00 | ₩429.51B |
| Orum Therapeutics | 475830.KQ | ₩19,270.00 | ₩409.15B |
| Genomictree | 228760.KQ | ₩11,320.00 | ₩277.64B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Prestige BioPharma from India
What Prestige BioPharma does
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. Prestige BioPharma operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
How are Prestige BioPharma dividends taxed for Indian investors?
Prestige BioPharma trades on the Korea Exchange but is domiciled in Singapore, so any withholding on its dividends follows that country's rules rather than those of South Korea. Dividends are taxed at your slab rate in India.
What tax do I pay in India when I sell Prestige BioPharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.